ANGLE PLC

Regulatory Filings • May 13, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5055E

Angle PLC

13 May 2013

For immediate release	13 May 2013

ANGLE plc

("ANGLE" or "the Company")

PARSORTIX CELL HARVESTING     

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that the Company has further extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function.

In January, ANGLE announced that, in addition to the Parsortix system's ability to capture and count very rare circulating tumour cells (CTCs) from the blood of cancer patients, the Company had developed a process for recovering captured cells from the Parsortix cassette for molecular analysis.  This process is referred to by ANGLE as "harvesting".

The Parsortix system's ability to harvest cells for analysis is a major advantage and key competitive differentiator.  Leading cancer research centres and hospitals in discussions with the Company have all emphasised the importance of this harvesting capability in meeting a key unmet medical need.

In around three months since establishing the original, manual version of the technique, ANGLE has now successfully automated this harvesting capability so that the Parsortix system can harvest captured CTCs using a new component and software control process integrated into the Parsortix machine.

The Parsortix system now has the potential to provide users with cancer cells for analysis from a simple blood test - a form of "liquid biopsy".  This opens the way for the cells to be analysed to identify the specific mutations of the individual patient's cancer using a wide range of genetic and molecular techniques.  This then offers the prospect of personalised medicine with drugs and other treatment selected specifically to address the individual patient's own cancer with better patient outcomes and lower costs of treatment.  

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We have seen widespread demand from researchers and clinicians for CTCs to be made available in a test tube after isolation from blood.  It is testimony to the versatility of our separation technology that we have been able to introduce and automate this capability in such a short time.  The consequent prospects for our Parsortix sales are significant." 

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Adrian Hargrave, Stephen Keys (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles www.buchanan.uk.com	020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFVTEAIFLIV